Hyperkalemia is a major barrier to RAASi use in patients with CKD and heart failure—yet these patients are the ones who need RAASi the most. Learn how you can navigate this paradox in clinical practice: ow.ly/XyIf50WLCmQ #MedicalEducation #HeartFailure

Iron deficiency anemia is common in patients with heart failure and is associated with increased mortality. However, many patients are not screened or treated for anemia. Discover how we can boost diagnosis for better outcomes: ow.ly/Vpyc50WLAQ1 #MedicalEducation

Iron deficiency is common in patients with heart failure, yet often underrecognized and undertreated. This program covers diagnosis and treatment of iron deficiency in heart failure based on current guidelines and evidence. Tune in here: ow.ly/2Qt150WPSPE #Cardiology

Hyperkalemia is a potentially life-threatening condition that disrupts potassium balance. Discover how early recognition and treatment are essential to reduce the risk of cardiac and muscular complications: ow.ly/7opo50WPT05 #Nephrology

The FAIR-HF2 trial showed that intravenous iron therapy with ferric carboxymaltose reduced cardiovascular death or first heart failure hospitalization by 21% in patients with HFrEF and iron deficiency. Learn more: ow.ly/CEU550WTx14 #HeartFailure #FAIRHF2 #Cardiology

Hyperkalaemia affects 6–10% of patients globally, with higher prevalence in those with CKD, heart failure, and diabetes, especially those on RAAS inhibitors. Read a consensus statement on management: ow.ly/n9ez50WTxfE #Hyperkalaemia #CardioRenalCare

RAAS inhibitors protect kidney and heart function but often raise potassium. Learn how potassium binders can support continued RAASi use in high-risk patients: ow.ly/l38A50X1LIm #Hyperkalemia #CKD #Cardiorenal #Nephrology

RAASi therapy saves lives, but hyperkalemia often forces discontinuation. Could long-term patiromer help preserve RAASi use and improve outcomes? This VA study suggests yes. Dive into the data: ow.ly/Eou850X1LNI #RAASi #CKD #PotassiumBinder

RAS blockers and MRAs reduce progression of CKD—but what happens when hyperkalemia gets in the way? Explore how clinicians can safely continue guideline-based therapy through effective hyperkalemia management: ow.ly/k1sI50X3X9W #Nephrology #CardioRenal #CME

Despite declining incidence in some regions, heart failure prevalence is increasing worldwide, fueled by aging, better survival, and evolving care. This review examines the global burden, disparities, and costs of HF. Read more: ow.ly/AmoZ50X3Xc5 #Cardiology #PublicHealth

How can oral potassium binders help maintain guideline-directed therapy in HFrEF and CKD? Compare real-world safety and efficacy data with experts in cardiology and nephrology. Start learning now: ow.ly/nme350X3ZoW #HeartFailure #CKD #Hyperkalemia

In patients with HFrEF and iron deficiency, oral iron did not improve exercise capacity after 16 weeks. No benefit was seen in peak V̇o2, 6MWD, NT-proBNP, or QoL. Check out the full study: ow.ly/qjqT50X3ZsH #HeartFailure #IronDeficiency #Cardiology

Concerned about hyperkalemia in patients with CKD and HFrEF ? Potassium binders like patiromer allow clinicians to continue outcome-improving therapies. Learn more: ow.ly/baTV50X9LAZ #CardioRenal #HeartFailure #CKD #PotassiumManagement

In a recent trial, patients with higher potassium levels were less likely to be uptitrated on ACEi/ARB. However, potassium did not impact outcomes or reduce the benefit of therapy. Check out the full study findings: ow.ly/Z7VE50X9LO2 #HFrEF #Potassium #RAASi

Hyperkalemia often limits the use of RAASi therapy in CKD and heart failure—yet these therapies save lives. Learn how novel potassium binders are helping clinicians maintain optimal RAASi use. Tune in now: ow.ly/Mk0650Xb2lE #CKD #HeartFailure #CME

A recent study showed that among patients without kidney disease, the risk of hyperkalemia was similar between ACE-I/ARB and β-blocker users. Elevated risk emerged only when eGFR was less than 60 mL/min/1.73m². Explore the research further: ow.ly/YAoi50Xb2LA #Nephrology

IV iron therapy has shown significant benefit in reducing HF hospitalizations, even in patients without anemia. Despite this, IV iron is still underutilized in HF care. Join Drs. Mentz and Ponikowski as they walk through the data: ow.ly/IRzZ50Xh5yG #HeartFailure

MRAs are recommended for most patients with HFrEF, but in the BIOSTAT-CHF study, only 56% were on one at baseline—and many stopped over time. Explore this real-world gap in heart failure treatment: ow.ly/Z4a750Xh5FA #HeartFailure #Cardiology

Presented at #ACC25, recent research confirms that IV iron can reduce CV death and hospitalizations in patients with HFrEF and iron deficiency. These data support continued use of IV iron for patients with HF. Learn more: ow.ly/Owj650XjXaY #HeartFailure #Cardiology

How can we optimize RAASi therapy despite the risk of hyperkalemia? Patiromer may help. A meta-analysis shows it reduces hyperkalemia and supports MRA titration in HF patients. Explore the research further: ow.ly/Xm2Z50Xk1G8 #HeartFailure #RAASi #MedTwitter